ArticleTranslational lung cancer research2025
Tumor rim-specific computed tomography radiomics improves prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant immunotherapy has revolutionized the treatment of non-small cell lung cancer (NSCLC), highlighting the need for accurate predictors of pathological complete response (pCR). This study aims to enhance pCR prediction to neoadjuvant immunotherapy in NSCLC patients by using radiomics analysis across various volumes of interest (VOIs) of the primary tumor on computed tomography (CT) images. Methods: A total of 229 NSCLC patients who received neoadjuvant immunotherapy between August 2018 and May 2024 were retrospectively analyzed. Radiomics models were built using four VOIs: gross tumor volume (GTV), tumor rim volume (TRV) which included 3 mm inward contraction and 3 mm outward expansion of the tumor boundary, PTV3 (3 mm beyond the tumor margin), and PTV6 (6 mm beyond the tumor margin). The performances of prediction models were evaluated in terms of discrimination, calibration and clinical usefulness. An independent neoadjuvant chemotherapy cohort was included to assess model specificity. To explore the biological mechanisms linked to the radiomics score, a genetic analysis was performed on 36 patients from The Cancer Imaging Archive (TCIA) dataset with available RNA-sequencing data. Results: Ninety-seven patients (42.4%) achieve pCR after neoadjuvant immunotherapy. The TRV radiomics model demonstrated the highest accuracy for the prediction of pCR in the validation cohort, with an area under the curve (AUC) of 0.827 and a 95% confidence interval (CI) ranging from 0.742 to 0.913, significantly outperforming GTV (0.631, 95% CI: 0.516-0.746), PTV3 (0.658, 95% CI: 0.546-0.770), and PTV6 radiomics models (0.689, 95% CI: 0.580-0.798) (all P<0.05). The TRV model exhibited limited performance in the chemotherapy cohort (AUC =0.519), indicating treatment specificity. Further radiogenomic analysis revealed that higher TRV radiomics score correlated with increased antitumor immune cell infiltration and upregulation of immune regulatory and cellular metabolism pathways. Conclusions: The proposed TRV radiomics model provided effective predictive performance of pCR in NSCLC patients treated with neoadjuvant immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.